These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 20145274)

  • 21. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
    Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
    Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus Entry.
    Park C; Min S; Park EM; Lim YS; Kang S; Suzuki T; Shin EC; Hwang SB
    J Virol; 2015 Oct; 89(19):10073-86. PubMed ID: 26202252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIM kinase inhibitors: an updated patent review (2016-present).
    Sharma A; Dubey R; Gupta S; Asati V; Kumar V; Kumar D; Mahapatra DK; Jaiswal M; Jain SK; Bharti SK
    Expert Opin Ther Pat; 2024 May; 34(5):365-382. PubMed ID: 38842051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
    Grundler R; Brault L; Gasser C; Bullock AN; Dechow T; Woetzel S; Pogacic V; Villa A; Ehret S; Berridge G; Spoo A; Dierks C; Biondi A; Knapp S; Duyster J; Schwaller J
    J Exp Med; 2009 Aug; 206(9):1957-70. PubMed ID: 19687226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
    Chen S; Yang Y; Yuan Y; Bo Liu
    Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
    Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
    Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.
    An N; Kraft AS; Kang Y
    J Hematol Oncol; 2013 Jan; 6():12. PubMed ID: 23360755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
    Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
    Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
    Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
    Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.
    Li YY; Mukaida N
    World J Gastroenterol; 2014 Jul; 20(28):9392-404. PubMed ID: 25071334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
    Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
    Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The serine/threonine kinase Pim-1.
    Bachmann M; Möröy T
    Int J Biochem Cell Biol; 2005 Apr; 37(4):726-30. PubMed ID: 15694833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.
    Kumar A; Mandiyan V; Suzuki Y; Zhang C; Rice J; Tsai J; Artis DR; Ibrahim P; Bremer R
    J Mol Biol; 2005 Apr; 348(1):183-93. PubMed ID: 15808862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using insights into Pim1 structure to design new anticancer drugs.
    Schenone S; Tintori C; Botta M
    Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
    Blanco-Aparicio C; Carnero A
    Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
    Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
    J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
    Siu A; Virtanen C; Jongstra J
    Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis.
    Quan J; Zhou L; Qu J
    Cell Mol Biol (Noisy-le-grand); 2015 Mar; 61(1):42-50. PubMed ID: 25817345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.